Male Athlete · 11 min read · Published 2026-05-16
Athlete Testosterone: T:C Ratio, mTORC1, and the Evidence for Creatine and CoQ10
Athletic performance optimization at the hormonal level requires moving beyond simple testosterone measurement toward a ratio-based and pathway-specific analysis. The testosterone:cortisol (T:C) ratio — originally validated in elite rowing and cycling cohorts as a predictor of overreaching syndrome — captures the anabolic:catabolic balance more faithfully than either hormone in isolation. A T:C ratio below 0.35 (in nmol/nmol units) consistently predicts impaired recovery, reduced force output, and increased injury risk in longitudinal training studies.
The molecular substrate of this ratio runs through two parallel pathways: testosterone drives anabolic signaling via the androgen receptor, which upregulates IGF-1 expression and activates mTORC1 (mechanistic target of rapamycin complex 1) — the master regulator of muscle protein synthesis. Cortisol drives catabolic signaling through glucocorticoid receptor activation of FOXO transcription factors, which upregulate MuRF-1 and atrogin-1 (ubiquitin ligases mediating muscle proteolysis). The nutritional and ergogenic literature contains several compounds with legitimate mechanistic and clinical evidence for favorably shifting this ratio — among them CoQ10, zinc, creatine, and magnesium — operating through distinct mechanisms that warrant separate analysis.
mTORC1 Anabolic Signaling: IGF-1, PI3K/Akt, and Testosterone Amplification
Testosterone's anabolic effect in skeletal muscle is mediated through two pathways: genomic (androgen receptor nuclear translocation → upregulation of IGF-1, MyoD, and muscle-specific genes) and non-genomic (rapid Akt phosphorylation via membrane-associated androgen receptor signaling). Both converge on mTORC1 activation. mTORC1 phosphorylates p70S6K1 (ribosomal S6 kinase 1) and 4E-BP1 (eIF4E-binding protein 1), rate-limiting translational regulators of muscle protein synthesis. Testosterone also directly upregulates satellite cell proliferation and myonuclear accretion, expanding the cellular machinery for adaptation.
IGF-1 operates in parallel: testosterone upregulates hepatic and local muscle IGF-1 expression, and IGF-1 activates the PI3K/Akt/mTORC1 axis independently, creating a feed-forward anabolic loop. The quantitative contribution of testosterone to mTORC1 activity is substantial — testosterone deficiency reduces basal muscle protein synthesis rates by approximately 30% in hypogonadal men, and this is restored to eugonadal levels with testosterone replacement. For athletes, this means that even modest reductions in free testosterone from training-induced HPA activation or micronutrient deficiency translate into measurable reductions in MPS and recovery capacity, not merely subjective performance decrements.
Creatine and the PCr Energy System: Type II Fiber Biochemistry
Creatine functions as a phosphate reservoir in the phosphocreatine (PCr) energy system: creatine kinase catalyzes the reversible reaction Cr + ATP ⇌ PCr + ADP, maintaining ATP:ADP ratio during high-intensity contraction. Type II (fast-twitch) fibers rely disproportionately on this system — PCr provides the primary ATP source for the first 6–10 seconds of maximal effort, before glycolytic flux can compensate. Creatine supplementation increases intramuscular PCr by approximately 20% at steady state (5 g/day), extending the duration of high-power output before glycolytic fatigue.
The testosterone-relevant question is whether creatine affects androgen metabolism. An often-cited 2009 study suggested creatine supplementation elevated DHT (dihydrotestosterone) by ~40% in rugby players. However, a well-powered 2025 RCT (PMID 40265319) — specifically designed to test this hypothesis — found no significant effect of creatine supplementation on DHT, testosterone, or the DHT:testosterone ratio in resistance-trained men. The earlier finding appears to have been a statistical artifact. Creatine's performance value stands independent of hormonal effects: its established benefits on lean mass, strength, and high-intensity performance capacity are mediated through PCr kinetics and cell volume changes, not androgen metabolism.
CoQ10 in Mitochondrial ATP Synthesis: Electron Transport and the 2025 Meta-Analysis
Coenzyme Q10 (ubiquinone) is an endogenously synthesized lipophilic quinone that functions as the mobile electron carrier between Complex I (NADH dehydrogenase) and Complex III (bc1 complex) in the mitochondrial inner membrane electron transport chain. In its reduced form (ubiquinol), CoQ10 also functions as a membrane-soluble antioxidant, quenching superoxide radicals generated at Complex I and III. Mitochondrial density is the primary determinant of aerobic capacity, and CoQ10 availability can become rate-limiting under conditions of high oxidative demand, statin use (statins inhibit the mevalonate pathway that synthesizes CoQ10's isoprenoid tail), or aging-related synthetic decline.
The 2025 meta-analysis (PMID 39830337) pooled data from 14 RCTs examining CoQ10 supplementation in men and found a standardized mean difference of +0.59 for testosterone (95% CI: 0.28–0.89, p < 0.001), with significant improvements also in sperm motility and antioxidant capacity. The testosterone mechanism is not fully elucidated but likely involves reduced oxidative stress in Leydig cells (mitochondria-dense cells with high steroidogenic demand) and improved mitochondrial ATP synthesis supporting StAR-dependent cholesterol transport. The effect size of 0.59 is moderate and clinically relevant — larger than most micronutrient interventions and comparable to ashwagandha in head-to-head magnitude terms.
Zinc Insufficiency in Athletes: Sweat Losses and Testosterone Consequences
Athletes represent a population at disproportionate risk for zinc insufficiency for two overlapping reasons: increased zinc losses through sweat (estimated 0.6–1.0 mg/L, with endurance athletes losing 1–2 mg/session in prolonged training) and elevated zinc requirements for exercise-induced protein synthesis and immune defense. Cross-sectional studies in male endurance athletes consistently show serum zinc concentrations 15–25% below reference ranges despite self-reported adequate dietary intake, likely because serum zinc is a poor proxy for intracellular zinc status in athletes.
Zinc's testosterone relevance operates through multiple mechanisms: zinc is required for LH receptor signaling transduction in Leydig cells (zinc-finger domain proteins in the receptor's intracellular signaling cascade), as an aromatase co-factor (zinc deficiency increases estrogen:testosterone ratio), and as a cofactor for 3β-HSD in the steroidogenic cascade. In zinc-deficient subjects, testosterone restoration with supplementation is rapid (2–4 weeks) and dose-responsive. In zinc-sufficient athletes, marginal additional benefit is seen — consistent with a deficiency-correction rather than supraphysiologic mechanism. Zinc bisglycinate at 30 mg/day in the AM stack replenishes training-related losses before the testosterone synthesis window of the following morning.
The bottom line
Athletic hormone optimization is not a single-variable problem. The T:C ratio captures the anabolic:catabolic balance; mTORC1 activation determines whether that balance translates into training adaptation; PCr kinetics determine whether type II fiber capacity is maximal at the point of demand; and mitochondrial CoQ10 availability determines whether Leydig cell steroidogenesis operates at full ATP-dependent capacity. Helian's athlete protocol maps these four mechanisms to a circadian AM/PM split: creatine, CoQ10, and zinc at AM (aligned with testosterone peak and pre-training energy priming), magnesium and ashwagandha at PM (T:C ratio restoration during overnight recovery). Each compound occupies a mechanistically distinct and non-redundant position.
Frequently Asked Questions
What T:C ratio threshold is clinically associated with overreaching syndrome, and how is it calculated?
The testosterone:cortisol ratio is typically expressed in nmol/nmol. A ratio below 0.35 has been validated as a predictor of overreaching syndrome in multiple elite athletic cohorts (originally Adlercreutz et al. 1986 in rowers, replicated in cyclists and team sport athletes). Calculation requires morning fasting measurements of both hormones — cortisol is typically 400–700 nmol/L at 08:00, testosterone 15–35 nmol/L, yielding a ratio of 0.02–0.09 in absolute units. Some labs report the ratio × 1000 for readability. The threshold is population-specific; individual athletes establish a personal baseline and track change from that reference.
Does the 2025 RCT (PMID 40265319) definitively settle the creatine-DHT question?
It is the best-powered study to date on this question, with pre-registration, blinding, and sufficient n to detect clinically meaningful DHT changes — and it found none. The original 2009 finding (van der Merwe et al.) had a small sample (n=20), single time point, and no correction for multiple comparisons. The DHT elevation found (±0.44 nmol/L at day 7) was within normal variation and did not persist. The mechanistic case for creatine affecting androgen metabolism was always weak — creatine does not enter the steroidogenic pathway, interact with 5α-reductase, or modulate androgen receptor. The 2025 null result is consistent with the mechanism and should be the operative evidence.
Is CoQ10's testosterone effect (SMD +0.59, PMID 39830337) mediated by antioxidant protection of Leydig cells or by direct mitochondrial ATP effects?
Likely both, and they are not fully separable. Leydig cells are among the most mitochondria-dense somatic cells in the body — appropriate, given that StAR-mediated cholesterol transport and CYP11A1 activity are ATP-dependent. Oxidative stress in Leydig cells (elevated 8-isoprostane and mitochondrial superoxide) is a documented consequence of intense training, and it impairs testosterone output. CoQ10 addresses both drivers: ubiquinol directly quenches mitochondrial superoxide (antioxidant mechanism), and ubiquinone transfers electrons at Complex I/II improving ATP yield (bioenergetic mechanism). The relative weight of each mechanism is not separable from existing RCT designs.
How should a male athlete interpret low-normal testosterone without clinical hypogonadism symptoms?
In athletic populations, the reference range (300–1000 ng/dL) was derived from sedentary controls and is systematically poorly calibrated for trained men. A recreational or competitive male athlete with testosterone in the 350–450 ng/dL range may be experiencing meaningful anabolic deficiency relative to his training demands — particularly if T:C ratio is below 0.35, recovery is impaired, and lean mass accrual has plateaued. The appropriate diagnostic question is not "are you clinically hypogonadal?" but "is your testosterone-cortisol balance adequate for your training load?" Nutritional gap analysis (zinc, vitamin D3, magnesium) should precede any pharmacological intervention.
Build your Male Athlete protocol.
Helian builds a circadian-timed supplement protocol for your exact hormonal profile — AM and PM windows, evidence-based dosages.
See your Male Athlete profile →